68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is
able to provide superior sensitivity and specificity to detect primary prostate tumor and its
metastases, like the widely studied 68Ga-PSMA-617. This pilot study was prospectively
designed to evaluate the early dynamic distribution of 68Ga-P16-093, a novel
radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-617 in the same group
of prostate cancer patients.